1. Home
  2. Glossary
  3. CD38

NAD+ glossary · Enzymes & pathways

What is CD38?

CD38 is an enzyme on the surface of many cells, especially immune cells, that breaks down NAD+. Studies in mice suggest rising CD38 is a key reason NAD+ falls with age.

  • CategoryEnzymes & pathways
  • Term16 of 30

Medically reviewed by Vanessa Niles, R.N., M.D., F.A.C.O.G. —

Definition

CD38, in plain English

CD38 is best known as a marker on immune cells. It's also an NAD+-consuming enzyme that breaks NAD+ down into nicotinamide and other products.

In a 2016 mouse study in Cell Metabolism, CD38 levels rose with age, and mice lacking CD38 kept higher NAD+ levels and better mitochondrial function (Camacho-Pereira et al.).

Type
NAD+-consuming enzyme
Found on
Immune and other cells
Linked to
Age-related NAD+ decline (mice)
CD38 enzyme on a cell surface breaking down NAD+, with a chart showing CD38 rising and NAD+ falling with age
In mice, CD38 rises with age as NAD+ falls.

How it connects

Scientists summarized the idea in a commentary titled 'Why NAD+ declines during aging: it's destroyed' (Schultz and Sinclair, 2016), pointing to CD38 as a major consumer.

Browse all 30 NAD+ terms

For your treatment

What CD38 means for NAD+ therapy

A CD38-targeting antibody, daratumumab, is used to treat multiple myeloma, for reasons unrelated to NAD+. No CD38 blocker is used to raise NAD+ in people.

  • Free online consultation with a licensed U.S. provider
  • NAD+ nasal spray or injection, plans from $166 a month if prescribed
  • NAD+ has no FDA-approved use; compounded NAD+ isn’t FDA-approved

Questions

CD38: common questions

What is CD38?

CD38 is an enzyme on the surface of many cells, especially immune cells, that breaks down NAD+. Studies in mice suggest rising CD38 is a key reason NAD+ falls with age.

Does CD38 cause aging?

No one has shown that. Mouse research links rising CD38 to falling NAD+, but how much this matters in people is still being studied.

Can I lower CD38?

There's no proven way to lower CD38 to raise NAD+ in people.

Does NAD+ therapy change how these enzymes work in people?

That hasn't been shown. Most research on NAD+ enzymes comes from cells and animals.

Are there medicines that target NAD+ enzymes?

Yes, in cancer care: PARP inhibitors treat some cancers, and a CD38 antibody (daratumumab) treats multiple myeloma. They aren't used to raise NAD+.

Why does enzyme research matter for NAD+ therapy?

It explains why NAD+ is worth studying. Plausible biology isn't the same as proof that NAD+ therapy helps people.

Official sources

CD38: sources and official resources

Official government and research sources behind this page, so you can check the facts yourself.

  1. NIH PubMedCamacho-Pereira et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction (2016)

    Mouse study linking rising CD38 with falling NAD+ during aging.

  2. NIH PubMedSchultz and Sinclair. Why NAD+ declines during aging: it's destroyed (2016)

    Commentary on CD38 as a major consumer of NAD+.

  3. NIH PubMed CentralCovarrubias et al. NAD+ metabolism and its roles in cellular processes during ageing (2021)

    Review of how NAD+ works in cells and how levels change with age.

  4. NIH PubMedNAD+ therapy in age-related degenerative disorders: a benefit/risk analysis (2020)

    Weighs early promise against the lack of long-term human trials.

Medically reviewed by Dr. Vanessa Niles, R.N., M.D., F.A.C.O.G., on October 12, 2026. This glossary is general education, not medical advice. NAD+ has no FDA-approved use, and compounded NAD+ is not FDA-approved or evaluated by the FDA for safety or effectiveness. Talk with a licensed provider before starting any supplement or treatment.

Questions about NAD+? Ask a provider

Book a free online consultation. A licensed U.S. provider reviews your health and, if NAD+ fits, prescribes the nasal spray or injection, with plans from $166 a month.

Book a free consultation